Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases
Sponsor
Boehringer Ingelheim (Industry)
Overall Status
Completed
CT.gov ID
NCT02184039
Collaborator
(none)
12,687
Study Details
Study Description
Brief Summary
Study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
12687 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Clinical Therapeutic Evaluation Program in Patients With Rheumatic Diseases
Study Start Date
:
May 1, 2003
Actual Primary Completion Date
:
Jul 1, 2004
Outcome Measures
Primary Outcome Measures
- Change in intensity of the symptoms measured with a four-point scale [Baseline, 30 and 90 days]
Secondary Outcome Measures
- Degree of satisfaction evaluated with a six point numerical rating scale [up to 90 days]
- Number of patients with adverse events [up to 90 days]
Eligibility Criteria
Criteria
Ages Eligible for Study:
12 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- none
Exclusion Criteria:
-
Hypersensitivity to meloxicam or to other NSAIDS
-
History of asthma, angioedema or urticaria secondary to NSAIDS
-
Pregnancy or lactation
-
Recent or current history of peptic ulcer disease, severe renal failure, severe hepatic failure
-
Age below of 12 years.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Boehringer Ingelheim
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT02184039
Other Study ID Numbers:
- 107.264
First Posted:
Jul 9, 2014
Last Update Posted:
Jul 9, 2014
Last Verified:
Jul 1, 2014